A regular internet blog written by Dr. Prodromos describing the latest advances in Stem Cell Medicine and related topics that you can use to help improve the health of yourself and your loved ones. (NOTE: your email address is kept strictly confidential)
Umbilical cord tissue-derived MSCs (mesenchymal stem cells), have been shown to improve post-acute COVID-19 symptomatology by significantly decreasing inflammatory cytokines, modulating the immune system, and improving recovery times. Cytokines are a category of small proteins important in cell signaling.
A stroke is one of the most common diseases, affecting almost 800,000 people annually in the United States. Recent research on mesenchymal stem cells have shown them to be potentially effective at treating strokes and improving the conditions of stroke patients. Mesenchymal stem cells can help by secreting growth factors to aid other recovery mechanisms such as neurons, synapses, and new blood vessels.
Kidney disease is a condition in which the kidneys become damaged and cannot filter blood properly. Kidney disease affects over 660,000 Americans and leads to 47,000 deaths per year in the United States. People with high blood pressure and diabetes are at greater risk for kidney disease. Treatment for kidney disease can be very expensive, and patients can wait years for treatment.
Stem cell therapy has become an integral piece in the search for an innovative method to treat both Type 1 and Type 2 Diabetes, as the push to move away from regular insulin injections for patients continues. Mesenchymal stem cells’ ability to morph or differentiate into different types of cells in the body makes them a strong candidate to combat the condition that affects hundreds of millions of people worldwide.
Mesenchymal stem cells (MSCs) innately migrate toward areas of inflammation. Research shows that when administered intravenously, mesenchymal stem cells cross the blood-brain barrier leading to various therapeutic effects.
